Generating AI analysis...
Revenue
$35.96B
++7.24% YoY
EPS (Basic)
$-4.45
-247.84% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $35.96B | $33.53B | +7.24% |
Cost of Revenue | $9.16B | $7.95B | +15.20% |
Net Income | $-9.02B | $6.26B | -244.02% |
EPS (Basic) | $-4.45 | $3.01 | -247.84% |
EPS (Diluted) | $-4.45 | $2.99 | -248.83% |
R&D Expense | $7.97B | $6.82B | +16.82% |
SG&A Expense | $6.28B | $5.7B | +10.16% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $93.67B | $91.26B | +2.64% |
Current Assets | $28.07B | $27.63B | +1.60% |
Total Liabilities | $76.47B | $62.2B | +22.94% |
Current Liabilities | $22.64B | $23.46B | -3.51% |
Stockholders' Equity | $17.14B | $29B | -40.89% |
Cash & Equivalents | $7.89B | $7.51B | +5.00% |
Long-Term Debt | $49.55B | $37.01B | +33.87% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $10.75B | $9.61B | +11.90% |
Investing Cash Flow | $-21.16B | $-949M | -2129.29% |
Financing Cash Flow | $6.77B | $-10.38B | +165.19% |
Dividends Paid | $3.65B | $3.58B | +1.70% |
Share Buybacks | $0 | $5.16B | -100.00% |
D&A | $7.72B | $7.3B | +5.81% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | -25.1% | — | — |
ROE | -52.6% | — | — |
ROA | -9.6% | — | — |
Current Ratio | $1.24 | — | — |
Debt to Equity | $4.461 | — | — |
Other companies in Pharmaceuticals